111 related articles for article (PubMed ID: 34563446)
1. Clinical Predictors of Response to Anti-PD-1 First-Line Treatment in a Single-Centre Patient Cohort: A Real-World Study.
Di Pietro FR; Verkhovskaia S; Mastroeni S; Carbone ML; Abeni D; Di Rocco CZ; Samà N; Zappalà AR; Marchetti P; De Galitiis F; Failla CM; Fortes C
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):e18-e24. PubMed ID: 34563446
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
3. Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.
Dimitriou F; Namikawa K; Reijers ILM; Buchbinder EI; Soon JA; Zaremba A; Teterycz P; Mooradian MJ; Armstrong E; Nakamura Y; Vitale MG; Tran LE; Bai X; Allayous C; Provent-Roy S; Indini A; Bhave P; Farid M; Kähler KC; Mehmi I; Atkinson V; Klein O; Stonesifer CJ; Zaman F; Haydon A; Carvajal RD; Hamid O; Dummer R; Hauschild A; Carlino MS; Mandala M; Robert C; Lebbe C; Guo J; Johnson DB; Ascierto PA; Shoushtari AN; Sullivan RJ; Cybulska-Stopa B; Rutkowski P; Zimmer L; Sandhu S; Blank CU; Lo SN; Menzies AM; Long GV
Ann Oncol; 2022 Sep; 33(9):968-980. PubMed ID: 35716907
[TBL] [Abstract][Full Text] [Related]
4. Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study.
van Zeijl MCT; Haanen JBAG; Wouters MWJM; de Wreede LC; Jochems A; Aarts MJB; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn EW; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven KJM; van den Eertwegh AJM
J Immunother; 2020 Oct; 43(8):256-264. PubMed ID: 32804914
[TBL] [Abstract][Full Text] [Related]
5. Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.
Pires da Silva I; Ahmed T; McQuade JL; Nebhan CA; Park JJ; Versluis JM; Serra-Bellver P; Khan Y; Slattery T; Oberoi HK; Ugurel S; Haydu LE; Herbst R; Utikal J; Pföhler C; Terheyden P; Weichenthal M; Gutzmer R; Mohr P; Rai R; Smith JL; Scolyer RA; Arance AM; Pickering L; Larkin J; Lorigan P; Blank CU; Schadendorf D; Davies MA; Carlino MS; Johnson DB; Long GV; Lo SN; Menzies AM
J Clin Oncol; 2022 Apr; 40(10):1068-1080. PubMed ID: 35143285
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience.
Nicholas MN; Khoja L; Atenafu EG; Hogg D; Quirt I; Butler M; Joshua AM
Melanoma Res; 2018 Dec; 28(6):571-577. PubMed ID: 30067547
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden.
Pietrantonio F; Loupakis F; Randon G; Raimondi A; Salati M; Trapani D; Pagani F; Depetris I; Maddalena G; Morano F; Corallo S; Prisciandaro M; Corti F; Guarini V; Bocconi A; Marra A; Belli C; Spallanzani A; Fassan M; Lonardi S; Curigliano G; Fucà G; Di Bartolomeo M; de Braud F
Oncologist; 2020 Sep; 25(9):803-809. PubMed ID: 32369650
[TBL] [Abstract][Full Text] [Related]
8. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.
Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457125
[TBL] [Abstract][Full Text] [Related]
9. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
[TBL] [Abstract][Full Text] [Related]
10. A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.
Ugurel S; Loquai C; Kähler K; Hassel J; Berking C; Zimmer L; Haubitz I; Satzger I; Müller-Brenne T; Mikhaimer NC; Becker JC; Kilian KJ; Schadendorf D; Heinzerling L; Kaatz M; Utikal J; Göppner D; Pföhler C; Pflugfelder A; Mössner R; Gutzmer R;
Ann Oncol; 2015 Mar; 26(3):573-82. PubMed ID: 25524477
[TBL] [Abstract][Full Text] [Related]
11. Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.
Pan M; Alavi M; Herrinton LJ
Perm J; 2018; 22():17-149. PubMed ID: 29616914
[TBL] [Abstract][Full Text] [Related]
12. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice.
Tjulandin S; Demidov L; Moiseyenko V; Protsenko S; Semiglazova T; Odintsova S; Zukov R; Lazarev S; Makarova Y; Nechaeva M; Sakaeva D; Andreev A; Tarasova A; Fadeyeva N; Shustova M; Kuryshev I
Eur J Cancer; 2021 May; 149():222-232. PubMed ID: 33872982
[TBL] [Abstract][Full Text] [Related]
13. Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma.
Chasseuil E; Saint-Jean M; Chasseuil H; Peuvrel L; Quéreux G; Nguyen JM; Gaultier A; Varey E; Khammari A; Dréno B
Acta Derm Venereol; 2018 Apr; 98(4):406-410. PubMed ID: 29327065
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
Ogata D; Haydu LE; Glitza IC; Patel SP; Tawbi HA; McQuade JL; Diab A; Ekmekcioglu S; Wong MK; Davies MA; Amaria RN
Cancer Med; 2021 Apr; 10(7):2293-2299. PubMed ID: 33686688
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies.
Frelau A; Jali E; Campillo-Gimenez B; Pracht M; Porneuf M; Dinulescu M; Edeline J; Boussemart L; Lesimple T
Melanoma Res; 2021 Jun; 31(3):208-217. PubMed ID: 33904517
[TBL] [Abstract][Full Text] [Related]
16. The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.
Botticelli A; Cirillo A; Scagnoli S; Cerbelli B; Strigari L; Cortellini A; Pizzuti L; Vici P; De Galitiis F; Di Pietro FR; Cerbelli E; Ghidini M; D'Amati G; Della Rocca C; Mezi S; Gelibter A; Giusti R; Cortesi E; Ascierto PA; Nuti M; Marchetti P
Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32353934
[TBL] [Abstract][Full Text] [Related]
17. Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma.
Pokorny R; McPherson JP; Haaland B; Grossmann KF; Luckett C; Voorhies BN; Sageser DS; Wallentine J; Tolman Z; Hu-Lieskovan S; Swami U
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500258
[TBL] [Abstract][Full Text] [Related]
18. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
19. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.
Czarnecka AM; Teterycz P; Mariuk-Jarema A; Lugowska I; Rogala P; Dudzisz-Sledz M; Switaj T; Rutkowski P
Target Oncol; 2019 Dec; 14(6):729-742. PubMed ID: 31754963
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy with toripalimab for lung adenocarcinoma in a real-world patient with an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 4: a case report.
Xue Y; Zheng K; Xue J
Ann Palliat Med; 2021 Sep; 10(9):10114-10123. PubMed ID: 34628932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
